Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ciclesonide ( Byk Gulden).

Gordon Dent1

  • 1University of Southampton School of Medicine, Division of Infection, Inflammation & Repair, Southhampton General Hospital, UK. g.dent@soton.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

British journal of pharmacology·2023
Same author

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.

British journal of pharmacology·2021
Same author

Evidence regarding the utility of multiple mini-interview (MMI) for selection to undergraduate health programs: A BEME systematic review: BEME Guide No. 37.

Medical teacher·2016
Same author

Synergic production of neutrophil chemotactic activity by colonic epithelial cells and eosinophils.

Immunobiology·2014
Same author

Eosinophil chemotaxis.

Methods in molecular biology (Clifton, N.J.)·2014

Ciclesonide, an inhaled corticosteroid, shows anti-inflammatory effects for asthma and COPD treatment. Clinical trials are ongoing, with potential launches and significant sales predicted.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Ciclesonide is a non-halogenated inhaled corticosteroid with anti-inflammatory properties.
  • It is under development for asthma and chronic obstructive pulmonary disease (COPD).

Purpose of the Study:

  • To evaluate the efficacy and safety of ciclesonide for respiratory conditions.
  • To assess different formulations including multidose powder, propellant-filled inhalers, and nasal sprays.

Main Methods:

  • Phase III clinical trials were conducted in the US and Europe.
  • Phase I and II trials were initiated in Japan.
  • Development involved multiple pharmaceutical companies including Byk Gulden, Aventis, and Teijin.

Main Results:

  • Ciclesonide demonstrated good efficacy without significant corticosteroid-associated systemic side effects.

Related Experiment Videos

  • Phase III trials for asthma were in progress by September 2001.
  • Projected sales forecasts indicated substantial market potential.

    • Conclusions:

    • Ciclesonide is a promising candidate for treating asthma and COPD.
    • Once-daily dosing and favorable safety profile support its therapeutic potential.
    • Regulatory submissions and product launches were anticipated in the early 2000s.